Serum interleukin-6 levels in patients with thrombocytosis.

Abstract

Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using an IL-6-responsive bioassay. A cohort of healthy volunteers with normal platelet counts was used to establish a control mean serum IL-6 level [2.19 U/ml +/- 1.08 SD (range 0-5.5)]. Patients with primary thrombocytosis had a mean serum IL-6 level not significantly different from controls. In comparison, serum IL-6 levels of patients with reactive thrombocytosis were significantly greater than controls (38.3 U/ml +/- 94.6; range 0-933; P < 0.001). Although no significant correlation was observed between the degree of serum IL-6 elevation and the height of the platelet count in any individual, elevated serum IL-6 was highly correlated with reactive thrombocytosis.

• Authors: C W Hollen, J Henthorn, J A Koziol, S A Burstein
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 8 Issue 3 Pg. 235-41 (Oct 1992) ISSN: 1042-8194 [Print] United States
• PMID: 1490150 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Interleukin-6

Topics

• Hematopoiesis
• Humans
• Inflammation (complications)
• Interleukin-6 (blood)
• Megakaryocytes (pathology)
• Myeloproliferative Disorders (blood, physiopathology)
• Neoplasms (complications)
• Platelet Count
• Postoperative Complications
• Thrombocythemia, Essential (blood, physiopathology)
• Thrombocytosis (blood, etiology, physiopathology)